10-Q: Agenus Inc. Reports Third Quarter 2024 Results Amidst Financial Uncertainty

Agenus Inc. reported its third quarter 2024 results, highlighting increased non-cash royalty revenue but also significant operating losses and concerns about its ability to continue as a going concern.

Summary

• Agenus Inc. reported a net loss of $66.4 million for the third quarter of 2024, compared to a net loss of $62.3 million for the same period in 2023.
• The company's non-cash royalty revenue increased to $24.7 million in Q3 2024 from $20.4 million in Q3 2023, primarily due to increased sales of GSK vaccines containing Agenus's STIMULON QS-21 adjuvant.
• Research and development expenses decreased by 20% to $41.1 million in Q3 2024, compared to $51.4 million in Q3 2023, due to reduced third-party services, personnel costs, and subsidiary activities.
• General and administrative expenses also decreased by 9% to $17.3 million in Q3 2024 from $18.9 million in Q3 2023.
• Interest expense, net, increased significantly to $35.7 million in Q3 2024 from $18.6 million in Q3 2023, driven by non-cash interest related to royalty purchase agreements.
• For the nine months ended September 30, 2024, the net loss attributable to Agenus Inc. common stockholders was $181.5 million, compared to $199.6 million for the same period in 2023.
• The company's cash and cash equivalents decreased to $44.8 million as of September 30, 2024, from $76.1 million at the end of 2023.
• Agenus has an accumulated deficit of $2.1 billion as of September 30, 2024, and $13.0 million of subordinated notes maturing in February 2025.
• The company has expressed substantial doubt about its ability to continue as a going concern for a period of one year after the date of filing this report, due to its liquidity needs.

Sentiment

Score: 3

Explanation: The document presents a mixed picture with some positive aspects like increased royalty revenue and reduced operating expenses, but the significant net loss, decreased cash reserves, and going concern warning heavily weigh down the sentiment. The company's reliance on external funding and the ongoing legal proceedings add to the negative outlook.

Positives

• Non-cash royalty revenue increased due to higher sales of GSK vaccines containing Agenus's adjuvant.
• Operating expenses, including research and development and general and administrative costs, decreased compared to the same period last year.
• The company has secured $25.9 million in net proceeds from at-the-market equity sales during the nine months ended September 30, 2024.
• Agenus is actively seeking additional funding through partnerships and other means to support its operations.

Negatives

• The company reported a net loss of $66.4 million for the third quarter of 2024.
• Interest expense increased significantly due to non-cash interest related to royalty purchase agreements.
• Cash and cash equivalents decreased by $31.3 million since the end of 2023.
• Agenus has an accumulated deficit of $2.1 billion and $13.0 million in subordinated notes due in February 2025.
• There is substantial doubt about the company's ability to continue as a going concern for the next year.

Risks

• The company's ability to continue as a going concern is uncertain due to its liquidity needs.
• Agenus is dependent on securing additional funding through partnerships, asset sales, or equity issuances.
• The company faces risks related to the development and regulatory approval of its product candidates.
• Agenus is subject to a securities class action lawsuit alleging false and misleading statements related to the efficacy and commercial prospects of botensilimab and balstilimab.
• The company received a subpoena from the SEC seeking records related to certain product candidates and other matters.

Future Outlook

Agenus believes its current cash resources will be sufficient to satisfy critical liquidity requirements through the end of the year and into 2025, but requires additional funding to support operations, meet its subordinated notes obligation, and execute its business plans. The company is in discussions with several entities to secure this funding.

Management Comments

• Management continues to address the Company's liquidity needs and has continued to adjust spending in order to preserve liquidity.
• Our CEO, Dr. Garo Armen has elected to receive his base salary and any potential bonus payments in stock rather than cash.
• We continuously evaluate the likelihood of success of our programs.

Industry Context

Agenus is operating in the competitive immuno-oncology field, where companies are developing novel therapies targeting cancer. The company's focus on combination therapies and its integrated capabilities are aimed at accelerating the development and commercialization of its product candidates. The company's reliance on partnerships and collaborations is a common strategy in the biotech industry to share development costs and risks.

Comparison to Industry Standards

• Agenus's reliance on royalty monetization and equity issuances for funding is a common practice among clinical-stage biotech companies, but the level of debt and the going concern warning are concerning.
• The company's focus on combination therapies aligns with current trends in immuno-oncology, where combining different treatment modalities is seen as a way to improve patient outcomes.
• The decrease in R&D spending is a common strategy for companies facing financial constraints, but it may also slow down the development of new product candidates.
• The company's integrated capabilities, including novel target discovery and cGMP manufacturing, are intended to provide a competitive advantage by accelerating development timelines, but the financial situation may limit the ability to fully leverage these capabilities.
• The termination of several collaboration agreements, such as with Incyte and BMS, is a setback and highlights the risks associated with relying on external partners for development and commercialization.

Legal Proceedings

• A putative securities class action lawsuit was commenced against Agenus and three current officers, alleging false and misleading statements related to botensilimab and balstilimab.
• Agenus received a subpoena from the SEC seeking records related to certain product candidates and other matters.

Related Party Transactions

• Agenus had a contract with Avillion Life Sciences LTD for clinical consulting services, where a former board member is CEO.
• Agenus expensed fees to Wolf, Greenfield & Sachs, P.C., where a current board member's spouse is a partner.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and the potential for further dilution.
• Employees may be affected by potential workforce reductions or changes in compensation.
• Customers and partners may be concerned about the company's ability to continue operations and fulfill its obligations.
• Creditors face increased risk of non-payment due to the company's financial difficulties.

Next Steps

• Agenus plans to continue discussions with potential partners and investors to secure additional funding.
• The company intends to proceed with the planned biologics license application submission for botensilimab/balstilimab.
• Agenus will continue to evaluate the likelihood of success of its programs and adjust funding accordingly.

Key Dates

Keywords

Agenus, biotechnology, immunotherapy, botensilimab, balstilimab, QS-21 adjuvant, clinical trials, royalty revenue, financial results, going concern, MiNK Therapeutics, SaponiQx